Compounds > isatoribine anhydrous
Page last updated: 2024-10-15

isatoribine anhydrous

Cross-References

ID SourceID
PubMed CID135409474
CHEMBL ID2105116
SCHEMBL ID127980
SCHEMBL ID12592999
MeSH IDM0169584

Synonyms (37)

Synonym
satoribine
immunosine
ana-245
122970-40-5
5-amino-3-.beta.-d-ribofuranosylthiazolo[4,5]pyrimidine-2,7(3h,6h)-dione
7-thia-8-oxoguanosine
5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-6h-thiazolo[4,5-d]pyrimidine-2,7-dione
ana 245
isatoribine
ana245
5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione
CHEMBL2105116
2dnt962h92 ,
isatoribine [usan:inn]
unii-2dnt962h92
7-deaza-7-thia-8-oxoguanosine
5-amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3h,6h)-dione
7-tog
thiazolo(4,5-d)pyrimidine-2,7(3h,4h)-dione, 5-amino-3-beta-d-ribofuranosyl-
7-thio-8-oxoguanosine
DB04860
SCHEMBL127980
isatoribine anhydrous
5-amino-3-.beta.-d-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3h,6h)-dione
isatoribine [inn]
TZYVRXZQAWPIAB-FCLHUMLKSA-N
5-amino-3-beta-d-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(6h)-dione
SCHEMBL12592999
DTXSID20924330
7-hydroxy-5-imino-3-pentofuranosyl-4,5-dihydro[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one
5-amino-3-|a-d-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione
Q27095551
5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione
BRD-K87535339-001-01-6
5-amino-3-d-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3h,6h)-dione
isatoribine free base
AKOS040745874

Dosage Studied

ExcerptReference
" However, dosing with masked oral prodrugs of TLR7 agonists, such as ANA-975, limits the adverse events associated with the activation of responsive gastrointestinal immune tissue."( Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.
Averett, D; Fletcher, S; Steffy, K, 2006)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID110461Ability to activate CBA/CaJ Mice spleen cells to proliferate in vitro by measuring new DNA synthesis in a [3H]thymidine incorporation assay at 0 mM1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID136825Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 100 mg/kg administration1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID202899Effect of compound on forest virus infection in mice, Mean survival time through 21 days at 100 mg/kg dose1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Guanosine analogues. Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents.
AID136831Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 200 mg/kg administration.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID110579Ability to activate CBA/CaJ Mice spleen cells to proliferate in vitro by measuring new DNA synthesis in a [3H]thymidine incorporation assay at 0.20 mM1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID136357Tested against Forest virus infection in mice at dose 100 mg/kg administered intraperitoneally in experiment 2; 11/12(92)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides.
AID1285200Antiviral activity against Semliki forest virus infected in mouse2016European journal of medicinal chemistry, May-04, Volume: 113Thiazolo[4,5-d]pyrimidines as a privileged scaffold in drug discovery.
AID134275Compound was tested for mean survival time through 21 days after administration of 100 mg/kg, 24 and 18 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID136827Compound was tested for its activity against intraperitoneal administration.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID136829Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 150 mg/kg oral administration.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID220074In vivo effect on murine NK cell activity in isolated CBA/CaJ mice spleen cells and cytotoxicity measured against YAC-1 cells at a targetor ratio 50:11990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID134437Tested against Forest virus infection in mice at dose 100 mg/kg administered intraperitoneally in experiment 21990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides.
AID134280Compound was tested for mean survival time through 21 days after oral administration of 150 mg/kg, 24 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID134438Tested against Forest virus infection in mice at dose 100 mg/kg administered intraperitoneally in experiment 31990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides.
AID136833Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 50 mg/kg administration1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID134278Compound was tested for mean survival time through 21 days after intraperitoneal administration of 150 mg/kg, 24 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID220072In vivo effect on murine NK cell activity in isolated CBA/CaJ mice spleen cells and cytotoxicity measured against YAC-1 cells at a targetor ratio 100:11990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID202897Effect against semliki forest virus infection in mice at an ip dose of 100 mg/kg; 11/121990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID136832Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 25 mg/kg administration1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID136828Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 150 mg/kg intravenous administration.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID224755Tested against Forest virus infection in mice at dose 100 mg/kg administered intraperitoneally in experiment 1; 9/12(75)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides.
AID202900Effect of compound on forest virus infection in mice, Mean survival time through 21 days at 200 mg/kg dose1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Guanosine analogues. Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents.
AID202898Effect against semliki forest virus infection in mice at an ip dose of 200 mg/kg; 11/121990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID202903Effect of compound on forest virus infection in mice at the dose of 200 mg/kg; Tested over 12 mice1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Guanosine analogues. Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents.
AID110578Ability to activate CBA/CaJ Mice spleen cells to proliferate in vitro by measuring new DNA synthesis in a [3H]thymidine incorporation assay at 0.05 mM1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID134281Compound was tested for mean survival time through 21 days after subcutaneous administration of 150 mg/kg, 24 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID202896Effect against semliki forest virus infection in mice at an ip dose of 200 mg/kg1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID134277Compound was tested for mean survival time through 21 days after administration of 25 mg/kg, 24 and 18 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID110577Ability to activate CBA/CaJ Mice spleen cells to proliferate in vitro by measuring new DNA synthesis in a [3H]thymidine incorporation assay at 0.01 mM1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID134276Compound was tested for mean survival time through 21 days after administration of 200 mg/kg, 24 and 18 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID136358Tested against Forest virus infection in mice at dose 100 mg/kg administered intraperitoneally in experiment 3; 11/12(92)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides.
AID192094Compound at a dose 100 mg/kg was administered to rat and Percent survivors after coronavirus infection in suckling rats.1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Modulation of leukocyte genetic expression by novel purine nucleoside analogues. A new approach to antitumor and antiviral agents.
AID202901Effect of compound on forest virus infection in mice at the dose of 100 mg/kg; Tested over 12 mice1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Guanosine analogues. Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents.
AID134279Compound was tested for mean survival time through 21 days after intravenous administration of 150 mg/kg, 24 hr prior to virus inoculation ( forest virus) in mice1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID118548Mean survival time of mice that died; survivors lived through 21 days1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Modulation of leukocyte genetic expression by novel purine nucleoside analogues. A new approach to antitumor and antiviral agents.
AID136826Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 100 mg/kg administration.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID202895Effect against semliki forest virus infection in mice at an ip dose of 100 mg/kg1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
AID1372795Antiviral activity against Semliki forest virus infected in Swiss Webster mouse assessed as mouse survival at 100 mg/kg, ip measured after 18 to 24 hrs2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
AID136830Compound was tested for its activity against forest virus infection in mice, activity was determined by measuring the number of survived mice after 150 mg/kg subcutaneous administration.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
AID134436Tested against Forest virus infection in mice at dose 100 mg/kg administered intraperitoneally in experiment 11990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides.
AID1372800Antiviral activity against Semliki forest virus infected in Swiss Webster mouse assessed as mean survival time at 100 mg/kg, ip2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
AID110580Ability to activate CBA/CaJ Mice spleen cells to proliferate in vitro by measuring new DNA synthesis in a [3H]thymidine incorporation assay at 0.40 mM1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.00)18.7374
1990's16 (64.00)18.2507
2000's4 (16.00)29.6817
2010's3 (12.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.14%)5.53%
Reviews4 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (78.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
clotrimazole
[no description available]		3.2710conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
olomoucine
olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.		3.27102,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
idoxuridine
[no description available]		3.2710organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		3.2710beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		1.9910acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9910azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		3.1310imidazoquinolineantineoplastic agent;
interferon inducer
cl 246738
3,6-bis(2-piperidinoethoxy)acridine trihydrochloride: immunomodulator; structure given in first source; RN given for tri-HCl		1.9910
inositol 1,4,5-trisphosphate
Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.		1.9710myo-inositol trisphosphatemouse metabolite
g(m1) ganglioside
G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.		1.9910alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		7.33192guanosines;
purines D-ribonucleoside		fundamental metabolite
ganciclovir
[no description available]		1.98102-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
7-deazaguanosine
7-deazaguanosine: structure given in first source		3.0810
8-thioguanosine
8-thioguanosine: lymphocyte activator		1.9710
8-bromoguanosine
[no description available]		1.9710purine nucleoside
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		210
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		3.4211
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Togaviridae
[description not available]		03.2360
Germinoblastoma
[description not available]		02.3820
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.3820
Benign Neoplasms
[description not available]		03.0910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0910
Chronic Hepatitis C
[description not available]		04.7321
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.		04.7321
Viral Diseases
[description not available]		02.6730
Virus Diseases
A general term for diseases caused by viruses.		02.6730
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		01.9810
Acquired Immune Deficiency Syndrome
[description not available]		01.9910
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.3820
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		01.9910
Leukemia L 1210
[description not available]		01.9710
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.3820
Plasma Cell Tumor
[description not available]		01.9710
Plasmacytoma
Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.		01.9710